Although remarkable clinical efficacy has been demonstrated in the treatment of patients with EGFR mutations the past decade, the majority of NSCLC patients acquire resistance to EGFR-TKIs, and new acquired mutations related to EGFR inhibitor treatment have continuously emerged [14]. Here, EGFR is linked to non-small cell lung carcinoma.